Early and prolonged oral edaravone for neuroprotection in acute ischemic stroke: the ERASE-STROKE randomized controlled phase 3 trial.
Yang Xiang, Wang-Sheng Jin, Xin-Chen Zhu et al.
✦ AI-curated · Sources linked
In 30 seconds
The ERASE-STROKE trial evaluated the effects of early and prolonged oral edaravone (TTYP01) on functional outcomes in patients with acute ischemic stroke. In this phase 3, multicenter, double-blind randomized controlled trial involving 614 patients, those receiving TTYP01 showed a significant improvement in excellent functional outcomes at 90 days, with 65.4% achieving a modified Rankin Scale score of 0-1 compared to 47.1% in the placebo group (odds ratio 2.12; P < 0.001).
Key findings
- 65.4% of patients receiving TTYP01 achieved an excellent functional outcome at 90 days.
- 47.1% of patients in the placebo group achieved an excellent functional outcome.
- Odds ratio for excellent outcome with TTYP01 was 2.12 (95% CI 1.53-2.94; P < 0.001).
- No significant differences in rates of symptomatic intracranial hemorrhage, mortality, or serious adverse events.
Why it matters
This study provides evidence that early and prolonged treatment with edaravone can enhance functional recovery in patients with acute ischemic stroke, potentially influencing treatment protocols for neuroprotection in this population.